



Diagnostics and Therapeutics Advances in Pancreatic Cancer

Guest Editors:

Dr. Andrea Belli

Division of HPB Surgical
Oncology, Istituto Nazionale
Tumori - Fondazione Pascale—
IRCCS, 80131 Napoli, Italy

Dr. Vincenza Granata

Istituto Nazionale Tumori IRCCS
Fondazione G. Pascale, Naples,
Campania, Italy

Deadline for manuscript
submissions:

30 October 2024

Message from the Guest Editors

Pancreatic cancers, and especially pancreatic ductal adenocarcinoma (PDAC), are one of the leading causes of cancer-related mortality worldwide. PDAC is characterized by its aggressive nature and dismal prognosis, with an overall 5-year survival rate of lower than 10%. Surgical resection still remains the most effective treatment but, unfortunately, is precluded from the vast majority of patients because of the metastatic or locally advanced disease status at diagnosis. Even in resected patients, cancer will recur in about 80% of cases. Therefore, accurate staging at diagnosis and even more accurate restaging after neoadjuvant therapies in the case of borderline resectable patients are of crucial importance to achieve efficient prognostic stratification and offer optimal treatment to each patient.

This Special Issue aims to provide a comprehensive overview of recent advances in terms of both innovations in the diagnosis of pancreatic cancer and the most advanced surgical techniques and innovative medical and multimodal strategies used in treatment. Study protocols and the results of clinical studies and translational research are also welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)